The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $884,453 Project Grant to Brigham & Women's Hospital Inc. to develop a rapid, cost-effective point-of-care (POC) diagnostic test for Hepatitis C Virus (HCV) detection. The 5-year project, which commenced on November 22, 2024, aims to create a highly sensitive and specific HCV antigen (Ag) testing solution that can streamline screening and diagnosis, particularly in resource-limited settings. This aligns with the World Health Organization's goal of reducing new HCV infections and mortality by 80% and 65%, respectively, by 2030. The project will leverage long-lasting luminescent cascade signal amplification technology to improve upon the limitations of existing laboratory-based HCV Ag assays, which lack the necessary sensitivity and specificity, especially for low viral load samples. Brigham & Women's Hospital Inc. is a subsidiary of the larger Partners Healthcare System, a prominent academic medical center and research institution with extensive federal contracting and grant award experience.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $884.5k | 11/22/24 |